885588-14-7Relevant articles and documents
Novel benzimidazole compounds
-
Paragraph 0144-0149, (2022/01/12)
The present invention relates to a class of compounds shown in formula (1) and a method of preparation thereof, and compounds of formula (1) and their various constituents, various crystal forms, pharmaceutically acceptable salts as EGFR inhibitors in the
ASK1 INHIBITING PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES
-
Paragraph 0150, (2019/02/02)
The present invention relates to pyrrolopyrimidine compounds according to Formula (I) and their use in the prophylaxis and/or treatment of pain, inflammatory conditions, cardiovascular diseases, neurodegenerative diseases, neurological diseases, complications of type I diabetes, cancer and/or fibrotic diseases. In a particular aspect, the present compounds are ASK inhibitors, particularly ASK1 inhibitors. The present invention also provides methods for the production of a compound of the invention, pharmaceutical compositions comprising a compound of the invention, the use of the compounds in the prophylaxis and/or treatment of pain, inflammatory conditions, cardiovascular diseases, neurodegenerative diseases, neurological diseases, complications of type I diabetes, cancer and/or fibrotic diseases. (Formula (I))
NITROGEN-CONTAINING HETEROCYCLIC AMIDE COMPOUND AND PHARMACEUTICAL USE THEREOF
-
Paragraph 0450-0453, (2019/08/29)
PROBLEM TO BE SOLVED: To provide a nitrogen-containing heterocyclic amide compound having pyruvate dehydrogenase kinase inhibitory activity, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same. SOLUTION: The present invention provides a compound of formula [I-a] or formula [II], or a pharmaceutically acceptable salt thereof (a bond of a dotted line: a single bond or a double bond. X1: C, N, O. X2: C, N. R1a: C1-4 alkyl, C1-4 alkyl carbonyl. R2: halogen, cyano, C1-4 alkyl. A1-A7: C, N, O. A8: C, N. R3, R4: H, C1-4 alkyl. Cy1: C4-6 cycloalkyl or the like. Cy2: C3-6 cycloalkyl or the like. m, t, w: 0, 1. n, r, v: 0, 1, 2.) SELECTED DRAWING: None COPYRIGHT: (C)2019,JPOandINPIT
HETEROARYL-CARBOXYLIC ACIDS AS HISTONE DEMETHYLASE INHIBITORS
-
Page/Page column 150, (2018/01/17)
The invention relates to heteroaryl-carboxylic acids as described herein, useful as histone demethylase inhibitors. The invention also relates to pharmaceutical compositions comprising these compounds and to their use in therapy, including e.g., in the treatment of cancer.
TRIAZOLOPYRIDINE COMPOUNDS
-
Page/Page column 27-28, (2012/06/16)
The invention is concerned with triazolopyridine compounds of formula (I) wherein R1, R2, R3 and R4 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These
TRIAZOLOPYRIDINE COMPOUNDS
-
Page/Page column 76-77, (2012/06/30)
The invention is concerned with triazolopyridine compounds of formula (I), wherein R1, R2 , R3 and R4 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. The
3-ARYLAMINO PYRIDINE DERIVATIVES
-
Page/Page column 38, (2008/06/13)
The invention provides novel, substituted 3-arylamino pyridine compounds (I) pharmaceutically acceptable salts, solvates and prodrug compounds thereof, wherein W, R1, R2, R9, R10, R11, R12, R13, R14 are as defined in the specification. Such compounds are